Last updated on November 2018

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Clinical Study Identifier: NCT03178552

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BO29554 ...

Kindai University Hospital
Osaka, Japan
1.51miles
  Connect »